Navidea Biopharmaceuticals News

0,2301 $ -20,35% -0,0588 $
In Euro: 0,1970 € | 19.09.18 21:59:24 Uhr AMEX | Mehr Kurse »
WKN: A1JSBX
ISIN: US63937X1037
US-Symbol: NAVB
Typ: Aktie

Navidea Biopharmaceuticals News

  
Mo Navidea Biopharmaceuticals Announces Acceptance into the National Institutes of Health Commercialization Accelerator Program Businesswire
Mo Navidea Biopharmaceuticals Announces Closing of a $3 Million Private Placement Businesswire
17.08.18 Navidea Biopharmaceuticals Announces Results of the Annual Shareholder Meeting Businesswire
16.08.18 Navidea Biopharmaceuticals Announces Details of 2018 Annual General Meeting Businesswire
15.08.18 Navidea Biopharmaceuticals Receives Noncompliance Notice From NYSE American Businesswire
08.08.18 Navidea Biopharmaceuticals Reports Second Quarter 2018 Financial Results Businesswire
12.07.18 Navidea Management to Host Moderated Q&A Webcast to Provide Corporate Update Businesswire
11.04.14 Navidea Pharmaceuticals Inc. Analyst Report: Long Term Market Potential of Lymphoseek does not Justify Current Valuation by BrokerBank Securities, Inc. PR Newswire
13.08.13 Robbins Arroyo LLP Is Investigating the Directors and Officers of Navidea Biopharmaceuticals, Inc. PR Newswire
03.06.13 SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Possible Breaches of Fiduciary Duty by the Board of Directors of Navidea Biopharmaceuticals, Inc. PR Newswire
11.09.12 Navidea Biopharmaceuticals-​Aktie: "buy" - Ladenburg Thalmann Aktiencheck
11.09.12 Navidea Biopharmaceuticals-​Aktie: Kursziel gesenkt - Rodman & Renshaw Aktiencheck
22.08.12 Navidea Biopharmaceuticals-​Aktie: "buy" - ThinkEquity Partners Aktiencheck
31.07.12 Alseres Pharmaceuticals, Inc. Reports License of Altropane® Worldwide Rights to Navidea Biopharmaceuticals, Inc. PR Newswire
23.07.12 Navidea Biopharmaceuticals-​Aktie: vielversprechende Pipeline - Hot Stocks Investor Aktiencheck

Newssuche

  

Videos

  
19.09.18
Blockchain: Für viele Branchen die Technologie der Zukunft? Philipp Sandner im Interview
}